Detailed price information for Engene Holdings Inc (ENGN-Q) from The Globe and Mail including charting and trades.

The average one-year price target for Capricor Therapeutics (NasdaqCM:CAPR) has been revised to $51.82 / share. This is an increase of 32.98% from the prior estimate of $38.96 dated December 3, 2025.

Detailed price information for Capricor Therap (CAPR-Q) from The Globe and Mail including charting and trades.

Piper Sandler raised the firm’s price target on Capricor Therapeutics (CAPR) to $45 from $20 and keeps an Overweight rating on the shares. The ...

SAN DIEGO, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics, today announced the ...

SAN DIEGO, July 28, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (CAPR) (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today ...

Capricor Therapeutics said the U.S. Food and Drug Administration has rejected its application seeking approval of its lead cell-therapy candidate Deramiocel in the neuromuscular genetic disease ...

Capricor Therapeutics, Inc. (NASDAQ:CAPR) stock is trading lower on Monday, with a session volume of 1.9 million compared to an average volume of 2.41 million, as per data from Benzinga Pro. According ...

— Dr. Binks joins Capricor in anticipation of potential approval of deramiocel in Q3 2025, bringing extensive experience in neuromuscular and rare diseases — SAN DIEGO, May 13, 2025 (GLOBE NEWSWIRE) - ...

Participants can use guest dial-in numbers above and be answered by an operator or click the Call me™ link for instant telephone access to the event. Webcast: Webcast Link - Click Here A replay of the ...

SAN DIEGO, April 01, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (CAPR) (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of ...

Capricor is also harnessing the power of its exosome technology, using its proprietary StealthX (TM) platform in preclinical development focused on the areas of vaccinology, targeted delivery of ...